PetMed Express Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PetMed Express in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PetMed Express stock.
View analyst ratings for PetMed Express or view top-rated stocks.

Wall Street analysts have given PetMed Express a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but PetMed Express wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

PetMed Express is scheduled to release its next quarterly earnings announcement on Monday, May 3rd 2021.
View our earnings forecast for PetMed Express.

PetMed Express, Inc. (NASDAQ:PETS) released its quarterly earnings results on Monday, January, 18th. The company reported $0.38 earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of $0.38. The company earned $65.90 million during the quarter, compared to analysts' expectations of $63.81 million. PetMed Express had a net margin of 9.82% and a trailing twelve-month return on equity of 22.79%. The company's quarterly revenue was up 10.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.34 EPS.
View PetMed Express' earnings history.

PetMed Express' stock was trading at $25.95 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, PETS shares have increased by 22.5% and is now trading at $31.78.
View which stocks have been most impacted by COVID-19.

PetMed Express announced a quarterly dividend on Wednesday, January 20th. Stockholders of record on Monday, February 1st will be paid a dividend of $0.28 per share on Friday, February 12th. This represents a $1.12 annualized dividend and a dividend yield of 3.52%. The ex-dividend date is Friday, January 29th.
View PetMed Express' dividend history.

PetMed Express pays an annual dividend of $1.12 per share and currently has a dividend yield of 3.45%.
View PetMed Express' dividend history.

1 Wall Street analysts have issued 12-month price targets for PetMed Express' stock. Their forecasts range from $41.00 to $41.00. On average, they expect PetMed Express' stock price to reach $41.00 in the next year. This suggests a possible upside of 29.0% from the stock's current price.
View analysts' price targets for PetMed Express or view top-rated stocks among Wall Street analysts.

5 employees have rated PetMed Express CEO Mendo Akdag on Glassdoor.com. Mendo Akdag has an approval rating of 46% among PetMed Express' employees. This puts Mendo Akdag in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to PetMed Express include Amazon.com (AMZN), Netflix (NFLX), Booking (BKNG), Expedia Group (EXPE), TripAdvisor (TRIP), Overstock.com (OSTK), 1-800-FLOWERS.COM (FLWS), Groupon (GRPN) and CarParts.com (PRTS).
View all of PETS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other PetMed Express investors own include Intel (INTC), NVIDIA (NVDA), AT&T (T), Cisco Systems (CSCO), Alibaba Group (BABA), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Verizon Communications (VZ), Netflix (NFLX) and Micron Technology (MU).

PetMed Express trades on the NASDAQ under the ticker symbol "PETS."

PetMed Express' stock is owned by a variety of retail and institutional investors. Top institutional investors include Profit Investment Management LLC (0.49%), Rothschild Investment Corp IL (0.15%), State of Alaska Department of Revenue (0.07%), Crossmark Global Holdings Inc. (0.04%), Everence Capital Management Inc. (0.04%) and NEXT Financial Group Inc (0.02%). Company insiders that own PetMed Express stock include Bruce S Rosenbloom, Gian Fulgoni, Menderes Akdag and Ronald J Korn.
View institutional ownership trends for PetMed Express.

PETS stock was sold by a variety of institutional investors in the last quarter, including Rothschild Investment Corp IL, and State of Alaska Department of Revenue. Company insiders that have sold PetMed Express company stock in the last year include Bruce S Rosenbloom, Gian Fulgoni, Menderes Akdag, and Ronald J Korn.
View insider buying and selling activity for PetMed Express or view top insider-selling stocks.

PETS stock was purchased by a variety of institutional investors in the last quarter, including Everence Capital Management Inc., Profit Investment Management LLC, Crossmark Global Holdings Inc., and NEXT Financial Group Inc.
View insider buying and selling activity for PetMed Express or or view top insider-buying stocks.

Shares of PETS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PETS stock can currently be purchased for approximately $31.78.

PetMed Express has a market capitalization of $644.21 million and generates $284.13 million in revenue each year.

PetMed Express employs 214 workers across the globe.

The official website for PetMed Express is www.1800petmeds.com.

PetMed Express is headquartered at 420 SOUTH CONGRESS AVENUE, DELRAY BEACH FL, 33445.

PetMed Express' mailing address is 420 SOUTH CONGRESS AVENUE, DELRAY BEACH FL, 33445. The company can be reached via phone at 561-526-4444.